Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Cancer
|
December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Bobbie J Rimel, Danielle Enserro, David P Bender, et al.
Research Square
|
May 15, 2024
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors
Mahesh Seetharam, Aurora Norman, Jacob Allred, et al.
ESMO Open
|
October 28, 2020
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Research Square
|
November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Dale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Cancer
|
December 21, 2023
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
Bobbie J Rimel, Danielle Enserro, David P Bender, et al.
Research Square
|
May 15, 2024
A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors
Mahesh Seetharam, Aurora Norman, Jacob Allred, et al.
ESMO Open
|
October 28, 2020
Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers
Gerardo Colon-Otero, Valentina Zanfagnin, Xiaonan Hou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2022
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study
Benoit You, Christopher Purdy, Larry J Copeland, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 16, 2024
NCCN Guidelines® Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024
Joyce Liu, Andrew Berchuck, Floor J Backes, et al.
Research Square
|
November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Dale Garsed, Tibor Zwimpfer, Sian Fereday, et al.
Page
of 2